Back to Results
First PageMeta Content
Myelofibrosis / Essential thrombocytosis / Myeloproliferative disease / Plateletpheresis / Ruxolitinib / Megakaryocyte / Platelet / Bone marrow / Anemia / Medicine / Biology / Anatomy


Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard
Add to Reading List

Document Date: 2015-02-08 17:25:15

Open Document

File Size: 2,49 MB

Share Result on Facebook

City

Scottsdale / Houston / Toronto / Lexington / Boston / New York / /

Company

9Promedior Inc. / /

Facility

Cancer Institute / University of British Columbia / Women’s Hospital / General Hospital / Paul’s Hospital / Sinai Medical Center / Cornell Medical Center / Marina Kremyanskaya5 / Anderson Cancer Center / Margaret Hospital / /

MedicalCondition

BM fibrosis / disease / leukopenia / bone marrow fibrosis / Thrombocytopenia / CA Myelofibrosis / Post-Essential Thrombocythemia / Post-Polycythemia Vera / Myeloproliferative neoplasms / Increased fibrosis / Anemia / myelofibrosis / fibrosis / /

MedicalTreatment

platelet transfusions / /

Organization

4Princess Margaret Hospital / 6Weill Cornell Medical Center / 5Mt Sinai Medical Center / Paul’s Hospital / Jason Gotlib10 1MD Anderson Cancer Center / 8Massachusetts General Hospital / 7Brigham and Women’s Hospital / University of British Columbia / 10Stanford Cancer Institute / Stanford / /

Person

Ann Hematol / /

/

Position

local pathologist / /

ProvinceOrState

Texas / British Columbia / New York / Arizona / Massachusetts / /

SocialTag